446 related articles for article (PubMed ID: 16981801)
21. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
Bansback NJ; Brennan A; Ghatnekar O
Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
[TBL] [Abstract][Full Text] [Related]
22. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Clark W; Jobanputra P; Barton P; Burls A
Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
[TBL] [Abstract][Full Text] [Related]
23. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
[TBL] [Abstract][Full Text] [Related]
24. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
26. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
28. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Foster RH
Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
30. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
31. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
32. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
[TBL] [Abstract][Full Text] [Related]
33. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
34. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
[TBL] [Abstract][Full Text] [Related]
35. An economic approach to health care.
Homik JE; Suarez-Almazor M
Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
[TBL] [Abstract][Full Text] [Related]
36. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
[TBL] [Abstract][Full Text] [Related]
37. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2004; 22(16):1071-95. PubMed ID: 15524495
[TBL] [Abstract][Full Text] [Related]
38. Review of health economics modelling in rheumatoid arthritis.
Emery P
Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
[TBL] [Abstract][Full Text] [Related]
40. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
